

March 18, 2025

KNOW LABS

Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor

SEATTLE--(BUSINESS WIRE)-- [Know Labs, Inc.](https://www.knowlabs.co) (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dielectric Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025.

The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership with companies and individuals who are leaders in the diabetes management field.

With its recent announcement of Know Labs Technology Licensing (KTL) there is a well-articulated path for partnership and licensing with a focus on rapidly advancing the Know Labs platform technology into the marketplace.

For more information on Know Labs, visit www.knowlabs.co.

About Know Labs Technology Licensing (KTL)

Know Labs Technology Licensing (KTL) is the dedicated licensing division of Know Labs, Inc. (NYSE American: KNW), facilitating the global adoption of its patented Radio Frequency Dielectric Spectroscopy (RFDS) technology. With an extensive intellectual property portfolio, a structured licensing framework, and the proprietary e-RFDS© digital watermark, KTL enables corporations, universities, and research institutions to innovate with confidence while securing their developments from counterfeiting and unauthorized use.

About Know Labs, Inc.

[Know Labs, Inc.](https://www.knowlabs.co)'s platform technology uses radio frequency dielectric spectroscopy (RFDS) to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company's first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration (FDA) clearance prior to its

introduction to the market. Other products, developed through Know Labs Technology Licensing ("KTL") program, may not require such prior FDA approval.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250318781363/en/>

Know Labs, Inc. Contact:

ask@knowlabs.co

Ph. (206) 903-1351

Source: Know Labs, Inc.